Difference between revisions of "PGMS-pathway control state"
From Bioblast
| Line 6: | Line 6: | ||
2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate | 2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate | ||
|info=[[Gnaiger | |info=[[Gnaiger 2020 BEC MitoPathways]] | ||
}} | }} | ||
::: ''More details'' | ::: ''More details'' | ||
| Line 19: | Line 16: | ||
== PGMS<sub>''L''</sub> == | == PGMS<sub>''L''</sub> == | ||
PGMS pathway in the LEAK state can be evaluated in the following SUIT protocols: | :::: PGMS pathway in the LEAK state can be evaluated in the following SUIT protocols: | ||
== PGMS<sub>''P''</sub> == | == PGMS<sub>''P''</sub> == | ||
PGMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols: | :::: PGMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols: | ||
:::*[[SUIT-008]] | :::*[[SUIT-008]] | ||
::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-008 O2 pfi D014]] | ::::* DL-Protocol for permeabilized fibers (pfi): [[SUIT-008 O2 pfi D014]] | ||
| Line 30: | Line 27: | ||
== PGMS<sub>''E''</sub> == | == PGMS<sub>''E''</sub> == | ||
PGMS pathway in the ET state can be evaluated in the following SUIT protocols: | :::: PGMS pathway in the ET state can be evaluated in the following SUIT protocols: | ||
:::*[[SUIT-001]] | :::*[[SUIT-001]] | ||
::::* DL-Protocol for isolated mitochondria and tissue homogenate (mt): [[SUIT-001 O2 mt D001]] | ::::* DL-Protocol for isolated mitochondria and tissue homogenate (mt): [[SUIT-001 O2 mt D001]] | ||
| Line 43: | Line 40: | ||
== Discussion == | == Discussion == | ||
:::: Recent studies showed that S- and NS-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in many SUIT protocols. This inhibition is less pronounced at higher succinate concentrations (10 mM up to 50 mM S). | :::: Recent studies showed that S- and NS-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in many SUIT protocols. This inhibition is less pronounced at higher succinate concentrations (10 mM up to 50 mM S). | ||
{{MitoPedia concepts | |||
|mitopedia concept=SUIT state | |||
}} | |||
Revision as of 20:04, 1 January 2021
- high-resolution terminology - matching measurements at high-resolution
PGMS-pathway control state
Description
PGMS: Pyruvate & Glutamate & Malate & Succinate.
MitoPathway control state: NS-pathway control state
2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate
Abbreviation: PGMS
Reference: Gnaiger 2020 BEC MitoPathways
PGMSL
- PGMS pathway in the LEAK state can be evaluated in the following SUIT protocols:
PGMSP
- PGMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols:
- DL-Protocol for permeabilized fibers (pfi): SUIT-008 O2 pfi D014
- DL-Protocol for permeabilized cells (pce): SUIT-008 O2 ce-pce D025
PGMSE
- PGMS pathway in the ET state can be evaluated in the following SUIT protocols:
- DL-Protocol for isolated mitochondria and tissue homogenate (mt): SUIT-001 O2 mt D001
- DL-Protocol for permeabilized fibers (pfi): SUIT-001 O2 pfi D002
- DL-Protocol for permeabilized cells (pce): SUIT-001 O2 ce-pce D003
- DL-Protocol for permeabilized PBMC and PLT: SUIT-001 O2 ce-pce D004
- DL-Protocol for permeabilized fibers (pfi): SUIT-008 O2 pfi D014
- DL-Protocol for permeabilized cells (pce): SUIT-008 O2 ce-pce D025
Discussion
- Recent studies showed that S- and NS-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in many SUIT protocols. This inhibition is less pronounced at higher succinate concentrations (10 mM up to 50 mM S).
MitoPedia concepts:
SUIT state
